Clinical trial NCT00658593: Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
Official title: A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Liver Cancer
Keywords: adenocarcinoma of the extrahepatic bile duct
unresectable extrahepatic bile duct cancer
recurrent extrahepatic bile duct cancer
adenocarcinoma of the gallbladder
adenocarcinoma with squamous metaplasia of the gallbladder
unresectable gallbladder cancer
recurrent gallbladder cancer
liver and intrahepatic biliary tract cancer
Lead sponsor: Canadian Cancer Trials Group
Sponsor class: NETWORK
First posted: 2008-04-15
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether gemcitabine is more effective when given together with or without capecitabine in treating patients with biliary cancer.

PURPOSE: This randomized phase III trial is studying giving gemcitabine together with capecitabine to see how well it works compared with giving gemcitabine alone in treating patients with locally advanced, unresectable, or metastatic biliary cancer.

Detailed description: OBJECTIVES:

Primary

* To compare overall survival (OS) rates in patients with locally advanced, unresectable or metastatic biliary tree cancer treated with combined gemcitabine hydrochloride and capecitabine vs. gemcitabine hydrochloride alone.

Secondary

* To compare progression-free survival (PFS) in this patient group.
* To compare response rates (complete response \[CR\] and partial response \[PR\]) in this patient group.
* To compare stable disease (SD) rates in this patient group.
* To compare rate of disease control (CR, PR and SD) in this patient group.
* To estimate and compare response duration in this patient group.
* To compare the effects of these treatments on measures of quality of life in this patient group using the EORTC QLQ-C30.
* To compare the nature, severity and frequency of toxicities between the two arms.

OUTLINE: This is a multicenter study. Patients are stratified according to tumour type (cholangiocarcinoma vs. gallbladder or biliary unknown), ECOG performance status (0-1 vs. 2), extent of disease (locally advanced vs. metastatic), and treatment center. Patients are randomized to 1 of 2 treatment arms.

* Arm I (Gemcitabine hydrochloride and capecitabine): Patients receive gemcitabine hydrochloride IV on days 1 and 8 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
* Arm II (Gemcitabine hydrochloride alone): Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at 12 weeks after randomization and 4 weeks after completion of study treatment.

After completion of study treatment, patients are followed at 4 weeks and then every 12 weeks thereafter.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically or cytologically proven adenocarcinoma of the biliary tree (intra- and extra-hepatic biliary ducts or gallbladder)
* Locally advanced, unresectable, or metastatic disease

  * Patients with pathologically confirmed metastatic adenocarcinoma consistent with biliary primary with clinical documentation of gallbladder or biliary tree involvement and no evidence of another primary adenocarcinoma are eligible
* Must have evidence of disease but measurable disease is not required

  * Chest x-ray and/or CT scan of the chest, CT scan or MRI of the abdomen, and other radiological examination to document all disease sites have been done within 28 days prior to randomization

    * No repeat scan needed if a negative scan was performed within 35 days prior to randomization
  * Patients who have only one site of disease located inside a previous radiotherapy field are eligible

    * Lesions within a previous radiotherapy field may be considered measurable if documented ≥ 20% increase in size
    * If the lesion size increase has not been documented since the completion of radiotherapy, and the lesion is still present (i.e. not CR), the lesion is considered evaluable for this trial
* Patients with biliary duct obstruction are eligible provided all of the following criteria are met:

  * Treatable, clinically relevant obstruction
  * Obstruction has been relieved by internal endoscopic drainage/stenting, palliative bypass surgery or percutaneous drainage prior to trial entry
* No ampullary carcinomas (i.e., arising from the ampulla of Vater)
* No central nervous system (CNS) metastases, including active, progressive brain or leptomeningeal metastases

  * Patients with focal neurological symptoms must have had a CT scan to rule out CNS metastases

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Minimum life expectancy of 12 weeks
* Able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in one of the validated languages
* Must be able to swallow and retain oral medication
* Hemoglobin \> 90 g/L
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Total bilirubin \< 3 times upper limit of normal(ULN)
* AST and/or ALT ≤ 5 times ULN
* Liver function tests stable and \< 3 times ULN
* Serum creatinine \< 160 µmol/L OR creatinine clearance \> 60 mL/min
* Negative pregnancy test
* Fertile patients and their partners must agree to use adequate contraception prior to study entry, throughout the study, and for a period of 4 weeks after cessation of protocol therapy
* Patients must be accessible for treatment and follow-up
* No known dihydropyrimidine dehydrogenase deficiency
* No known hypersensitivity to gemcitabine or capecitabine
* No other active medical condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy, including, but not limited to, any of the following:

  * Unstable angina
  * Uncontrolled arrhythmia
  * Heart failure
* No other condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol
* No other malignancies except adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for \> 5 years

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy for advanced or metastatic disease unless used in the following circumstances:

  * Fluorouracil or gemcitabine given concurrently with radiotherapy as a radiosensitizer, completed more than 3 months prior to randomization
  * Fluorouracil given as adjuvant treatment following surgery, completed at least 1 year prior to randomization
* No major surgery within 4 weeks of randomization
* No prior treatment with another investigational agent within 2 weeks of randomization
* At least 4 weeks from randomization since completion of prior radiotherapy and recovered

  * Patients may be randomized within the required 4 weeks if short course (\< 5 fractions) of non-myelosuppressive radiotherapy was given
* Concurrent palliative radiation to a known site of bone metastasis allowed provided that the criteria for disease progression are otherwise not met
* No other concurrent anti-cancer therapy (cytotoxic, biological/immunotherapy or radiotherapy other than for known bone metastases as specified above)
* No other concurrent investigational drug therapy

Primary outcomes:
measure: Overall survival
Secondary outcomes:
measure: Progression-free survival
measure: Response rates (complete response [CR] and partial response [PR])
measure: Rate of stable disease (SD)
measure: Rate of disease control (CR, PR, and SD)
measure: Response duration
measure: Quality of Life
measure: Toxicity
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre - Calgary
state: Alberta
city: Edmonton
country: Canada
facility: Cross Cancer Institute at University of Alberta
state: Alberta
city: Surrey
country: Canada
facility: BCCA - Fraser Valley Cancer Centre
state: British Columbia
city: Vancouver
country: Canada
facility: British Columbia Cancer Agency - Vancouver Cancer Centre
state: British Columbia
city: Ottawa
country: Canada
facility: Ottawa Hospital Regional Cancer Centre - General Campus
state: Ontario
city: St. Catharines
country: Canada
facility: St. Catharines General Hospital at Niagara Health System
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Hospital
state: Ontario
city: Greenfield Park
country: Canada
facility: Hopital Charles Lemoyne
state: Quebec
Study officials:
affiliation: Princess Margaret Hospital, Canada
name: Jennifer Knox, MD
role: STUDY_CHAIR
References: